|
[½»Á÷]
±¾ÈËÒÑÕÐÂú£¬Ð»Ð»¡£×£¸÷λ¿¼ÉúÒ»ÇÐ˳Àû¡£
°²»ÕÒ½¿Æ´óѧÉúÃü¿ÆѧѧԺ ÖܿɳɽÌÊÚ¿ÎÌâ×éÏÖÕÐÊÕµ÷¼Á˶ʿÑо¿Éú2Ãû£¬ÎÒÃǹØ×¢ÓÚÖ×Áö´úл¡¢Ö×ÁöתÒÆ¡¢°ÐÏòÒ©Î↑·¢µÈÏà¹ØÑо¿£¨ÏêϸÑо¿ÄÚÈݺͿÆÑгɹûÏê¼ûÏÂÁУ©£¬»¶ÓÓÐÒâÓÚÖ×ÁöÑо¿µÄѧÉú¼ÓÈëÎÒÃÇÍŶӡ£ÎÒÃÇÄ¿Ç°Ö»ÄÜÕÐÊÕÉúÎïѧÏà¹Øרҵ£¨07¿ªÍ·£©µÄѧÊõÐÔ˶ʿµ÷¼ÁÉú¡£
·½Ê½£º
½«¸öÈ˼òÀú¡¢¿¼Ñгɼ¨ µÈ£¬·¢ËÍÖÁÎÒÓÊÏ䣺 zhoukecheng@ahmu.edu.cn, Óʼþ±êÌâ×¢Ã÷¡°ÐÕÃû+±¨¿¼Ñ§Ð£+·ÖÊý ¡£
Ñо¿Éú×îµÍÒªÇó£¨2Ãû£©£º
1. ´ïµ½°²»ÕÒ½¿Æ´óѧÑо¿Éú¼ȡ×îµÍ±ê×¼¡£
2. ÓÐÖ¾ÓÚ´ÓÊ¿ÆÑй¤×÷£¬³ÏʵÉϽø¡£
3. ͨ¹ýÓ¢ÓïÁù¼¶ÕßÓÅÏÈ¡£
´ýÓö£º
1. Ìṩѧҵ½±Ñ§½ð×ÊÖú¡£
2. ÌṩһÁ÷µÄ¿ÆÑÐѧϰ»·¾³¡¢ÏȽøµÄ¿ÆÑÐÀíÄîºÍÁ¼ºÃµÄ¿ÆÑпÎÌâ¡£
3. Ìṩ¹úÄÚѧÊõ»áÒé½»Á÷µÄ»ú»á¡£
4. ¶ÔÓÚÓÅÐãµÄ±ÏÒµÉú£¬¿ÉÒÔÌṩ±¾ÊµÑéÊÒÃâÊÔת²©»ú»á¡£
5. ¶ÔÓÚÌرðÓÅÐãµÄ±ÏÒµÉú£¬¿ÉÒÔ°ïÖúÁªÏµºÍÍƼöÖÁºÕ¶ûÐÁ»ù´óѧҽѧԺ»ò·ÒÀ¼¹ú¼ÒҽѧÑо¿ÖÐÐļÌÐøÉîÔì¡£
¿ÎÌâ×鸺ÔðÈ˼ò½é
ÖÜ¿É³É ½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦£¬¶«ÄÏѧÕߣ¬Ñ§¿Æ×鸺ÔðÈË
¸öÈËÖ÷Ò³£ºhttp://life.ahmu.edu.cn/teacher- ... c0813.html?type=all
µç×ÓÓʼþ£ºzhoukecheng@ahmu.edu.cn
¸öÈ˼ò½é£º
²©Ê¿±ÏÒµÓÚÊÀ½çÇ°100Ãû¸ßУºÕ¶ûÐÁ»ù´óѧ£¬2020Äêͨ¹ý°²»ÕÒ½¿Æ´óѧ¡°¶«ÄÏÈ˲żƻ®¡±ÕÐƸÖÁ°²»ÕÒ½¿Æ´óѧÉúÃü¿ÆѧѧԺ¡£ÏÖΪ°²»ÕÒ½¿Æ´óѧ½ÌÊÚ£¬¡°¶«ÄÏѧÕß¡±£¬Ñ§¿Æ×鸺ÔðÈË¡£ÔøÖ÷³ÖºÍ²ÎÓë¶àÏî¹úÄÚÍâÖØ´ó¿ÆÑлù½ðÏîÄ¿£¬ÔÚÖ×ÁöÓë´úлÑо¿ÁìÓò, ½øÐÐÁ˳¤ÆÚϵͳ¡¢ÏµÍ³µÄ¹¤×÷£¬ÓÐÊ®¶àÄêµÄ¿Æѧ»ýÀÛ, ÔÚ¸ÃÁìÓòµÄÖøÃûÆÚ¿¯£¬Èçacs central science¡¢molecular cancerµÈ£¬·¢±í¶àƪ¸ßˮƽÂÛÎÄ£¬È¡µÃÏÔÖøµÄÑо¿³É¹û¡£
¸öÈ˾Àú
2020 -ÖÁ½ñ °²»ÕÒ½¿Æ´óѧÉúÃü¿ÆѧԺ£¬½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦£¬Ñ§¿Æ×鸺ÔðÈË£¬¶«ÄÏѧÕß
2014.08-2020 ºÕ¶ûÐÁ»ù´óѧҽѧԺ£¬²©Ê¿
2011.09-2014.07£¬Öйú¿ÆѧԺÀ¥Ã÷¶¯ÎïÑо¿Ëù£¬Ë¶Ê¿
2007.09-2011.07£¬°²»Õʦ·¶´óѧÉúÃü¿ÆѧԺ£¬Ñ§Ê¿
Ò»¡¢¸öÈËÈÙÓþ
1. ºÕ¶ûÐÁ»ù´óѧ biomedicum »ù½ð»á£¬¡°ÇàÄê¿Æѧ¼Ò¡± ÈÙÓþ³ÆºÅ£¬2019
2. ºÕ¶ûÐÁ»ù´óѧ biomedicum »ù½ð»á£¬¡°ÇàÄê¿Æѧ¼Ò¡± ÈÙÓþ³ÆºÅ£¬2018
3. ¹ú¼ÒÁôѧ»ù½ðί, ¡°¹ú¼ÒÓÅÐã×Ô·ÑÁôѧÉú½±Ñ§½ð¡±£¬2016
4. Öйú¿ÆѧԺ´óѧ, ¡°ÓÅÐãѧÉú¸É²¿¡±¼°¡°ÈýºÃѧÉú¡±³ÆºÅ£¬2012-2013
5. Öйú¿ÆѧԺ´óѧ, ¡°ÓÅÐãѧÉú¸É²¿¡±¼°¡°ÈýºÃѧÉú¡±³ÆºÅ£¬2011-2012
6. °²»Õʦ·¶´óѧ, ¡°Ñ§Éú¶þµÈ½±Ñ§½ð¡±£¬2008
¶þ¡¢Ñо¿ÁìÓò
ÎïÖʺÍÄÜÁ¿´úлÊÇÉúÃü»î¶¯µÄ»ù´¡£¬Æä´úлÎÉÂÒÓë·ÊÅÖ¡¢ÐÄѪ¹Ü¼²²¡¼°Ö×ÁöµÈ¼²²¡Ï¢Ï¢Ïà¹Ø¡£Ô½À´Ô½¶àµÄÑо¿Ö¤ÊµÖ×Áöϸ°û´úлÖرà³ÌÊÇÖ×Áö·¢Éú·¢Õ¹¹ý³ÌÖÐ×îÏÔÖøÌØÕ÷Ö®Ò»£¬Í¬Ê±¶ÔÖ×Áö´úл·Ö×Ó»úÖƼ°°ÐÏòÖ×Áö´úл;¾¶µÄÑо¿ÒѳÉΪÖ×ÁöÑо¿ÁìÓòµÄÈȵ㡣±¾¿ÎÌâ×éÖ÷ÒªÀûÓûùÒò±à¼¡¢»îϸ°û³ÉÏñ¡¢´úл×éѧ·ÖÎöµÈ¼¼Êõ£¬ÖÂÁ¦ÓÚ½ÒʾÖ×Áö·¢Õ¹¹ý³ÌÖдúлÎï¡¢¹Ø¼üøºÍ¹Ø¼üתÔ˵°°×µÄ¹¦ÄܺͷÖ×Ó»úÖÆ¡£
Ö×Áö´úлÖرà³Ìµ÷¿Ø×ÅÒ©ÎïÒ׸ÐÐÔ£¬Ò²ÊÇÒý·¢ÄÍÒ©µÄÖØÒª»úÖÆ¡£Îª´Ë£¬±¾¿ÎÌâ×é¶ÔDZÔÚÖ×Áö´úл¹Ø¼ü·Ö×Ó½øÐиßͨÁ¿Ò©Îïɸѡ£¬¼´´ÓÒѾÉÏÊеÄÒ©ÎïÖУ¬ÔËÓøßͨÁ¿É¸Ñ¡Æ½Ì¨£¬µÃµ½¾ßÓп¹°©Ð§Ó¦µÄÒ©ÎËæºó½øÐÐÌåÍâÌåÄÚʵÑé¶àά¶ÈÑéÖ¤£¬ÆäÖоºÕùµÄ½¹µãÔÚÓÚÐÂҩɸѡ£¬µÍºÄ¡¢¸ßЧÂÊɸѡ³öÐÂÒ©ÊÇÎÊÌâµÄºËÐÄ£¬ÆäÄ¿±êÊÇËõ¶ÌÐÂÒ©·¢Ïֵijɱ¾ºÍʱ¼ä¡£
ͬʱ£¬±¾¿ÎÌâ×é¶ÔÖ×ÁöÊý¾Ý¿â½øÐÐÍÚ¾òºÍ·ÖÎö£¬ÀûÓÃÈ˹¤ÖÇÄÜ»úÆ÷ѧϰ¶ÔÏÖÓеÄʵÑéÊý¾Ý¡¢Ò©Îïɸѡ½á¹û£¬½øÐбȶԡ¢·ÖÎö¡¢ÕûºÏºÍÔ¤²â£¬ÀûÓüÆËã»úÓïÑÔpythonºÍ×Ô¶¯»¯ÒÆÒºÆ÷¸¨ÖúÊý¾Ý·ÖÎöºÍʵÑéÁ÷³Ì¸ßЧÂʵÄÑз¢¡£
Èý¡¢´ú±íÐÔÂÛÎÄ£º
1. kecheng zhou#, andrea dichlberger#, hector martinez-seara, thomas nyholm, shiqian li, young ah kim, iipo vattulainen, elina ikonen, tomas blom*. ¡°a ceramide-regulated element in the late endosomal protein laptm4b controls amino acid transporter interaction¡±. acs central science. 2018; 4 (5): 548¨c558.
2. minxia liu#, kecheng zhou# and yi cao*. ¡°mcrs1 overexpression, which is specifically inhibited by mir-129-1-3p, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer¡±. molecular cancer. 2014; 13:245.
3. kecheng zhou, andrea dichlberger, elina ikonen, tomas blom*. ¡°laptm4b-24 is the predominant protein isoform in human tissues and undergoes rapid, nutrient regulated turnover¡±. the american journal of pathology. 2020; 190(10): 2018-2028.
4. minxia liu#, kecheng zhou#, yunchao huang and yi cao*. ¡°the candidate oncogene (mcrs1) promotes the growth of human lung cancer cells via the mir-155-rb1 pathway¡±. journal of experimental & clinical cancer research. 2015; 34(1):121.
5. andrea dichlberger, kecheng zhou, nils bäck, thomas nyholm, anders backman, peter mattjus, elina ikonen, tomas blom. ¡°laptm4b controls the sphingolipid and ether lipid signature of small extracellular vesicles¡±. biochim biophys acta mol cell biol lipids. 2021; 1866(2): 158855.
6. kecheng zhou#, minxia liu# and yi cao*, ¡°new insight of micrornas function in cancer: oncogene-microrna-tumor suppressor gene network¡±. frontiers in molecular bioscience. 2017; 4:46.
7. minxia liu#, kecheng zhou# and yi cao*, ¡°microrna-944 inhibits cell growth by targeting epha7 in non-small cell lung carcinoma.¡± international journal of molecular sciences. 2016; 17:1493.
8. kecheng zhou and tomas blom*. ¡°trafficking of simple bioactive sphingolipids: lessons from cells and model membranes.¡± lipid insights. 2015; 8(suppl 1):11-20.
ËÄ¡¢Ñ§ÊõÈÎÖ°
1. Áô·Ò»ªÈËÉúÃü¿Æѧлá, 2016 Äê-ÖÁ½ñ; coordinator¡£
2. frontiers of geneticsÔÓÖ¾, 2020 Äê-ÖÁ½ñ; guest editor¡£
3. Å·ÖÞ·Ö×ÓÉúÎïѧʵÑéÊÒ(embl)ʵ¼ù¿Î³Ì(µ°°×ÖÊ - Ö¬ÖÊÏ໥×÷ÓÃ:ÏȽøʵÑéºÍ¼ÆËã»ú¹¤¾ß), ·ÒÀ¼ºÕ¶ûÐÁ»ù,2017 Äê 7 Ô 2 ÈÕÖÁ 9 ÈÕ; ¿Î³Ì½²Ê¦¼°×é֯ίԱ»á³ÉÔ±¡£
4. ·ÒÀ¼¿ÆѧԺ׿ԽÖÐÐÄ×ÊÖúÏîÄ¿¡°prolipids¡±,2018-2020; ѧÉúίԱ»á³ÉÔ±¡£
5. prolipids Ïļ¾ÉúÎïĤÑÐÌÖ»á,·ÒÀ¼ºÕ¶ûÐÁ»ù,2019 Äê 6 Ô 10 ÈÕÖÁ 13 ÈÕ; ×é֯ίԱ»á ³ÉÔ±¡£
6. Äê¶È calsif(Áô·Ò»ªÈËÉúÃü¿Æѧлá)»áÒé,·ÒÀ¼ºÕ¶ûÐÁ»ù,2016 Äê 9 Ô 17 ÈÕ; ×é֯ίԱ»á³ÉÔ±¡£
7. µÚÁù½ìÖзÒÉúÃü¿ÆѧÂÛ̳,·ÒÀ¼ºÕ¶ûÐÁ»ù,2015 Äê 8 Ô 17 ÈÕÖÁ 18 ÈÕ; ×é֯ίԱ»á³ÉÔ±¡£
8. Å·ÖÞ°©Ö¢Ñо¿Ð»á,2018-ÖÁ½ñ; »áÔ±¡£
Îå¡¢²ÎÓë»áÒé
(»áÒ鱨¸æ):
1. ÑÇÖÞÀäȪ¸Û»áÒ飬ÖйúËÕÖÝ£¬2019Äê9ÔÂ2-6ÈÕ£¬»áÒ鱨¸æºÍº£±¨Õ¹Ê¾¡£
2. µÚ59½ì¹ú¼ÊÖ¬Àà¿Æѧ»áÒ飨icbl»áÒ飩£¬·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2018Äê9ÔÂ4ÈÕÖÁ7ÈÕ; »áÒ鱨¸æ¡£
3. ºÕ¶ûÐÁ»ù´óѧϵͳÉúÃü¿Æѧ£¨ils£©²©Ê¿ÑÐÌֻᣬ·ÒÀ¼tvärminne£¬2018Äê5ÔÂ7ÈÕÖÁ8ÈÕ; Ö÷½²ÈË£¬ÌØÑû±¨¸æ¡£
4. µÚ12½ìsphingolipid¾ãÀÖ²¿»áÒ飬Òâ´óÀûÎ÷Î÷Àﵺ£¬2017Äê9ÔÂ6ÈÕÖÁ10ÈÕ; »áÒ鱨¸æ; ¡°ÓÅÐã»ã±¨½±¡±¡£
5. febs ÏȽøÖ¬ÖÊÑо¿»áÒ飬ϣÀ°spetsesµº£¬2016Äê9ÔÂ1ÈÕÖÁ8ÈÕ; »áÒ鱨¸æºÍº£±¨Õ¹Ê¾¡£
6. ¹¦ÄÜÐÔÖ¬ÖÊ×éѧÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2016Äê4ÔÂ20ÈÕ; »áÒ鱨¸æ¡£
7. ºÕ¶ûÐÁ»ù´óѧ¸Éϸ°û¼°´úлÑо¿ÏîÄ¿Ô¶ÈÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2019Äê5ÔÂ8ÈÕ; »áÒ鱨¸æ¡£
8. ·ÒÀ¼¿ÆѧԺ׿ԽÑо¿ÖÐÐÄ£¨prolipids£©Ô¶ÈÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2018Äê4ÔÂ20ÈÕ; »áÒ鱨¸æ¡£
9. minerva ÉúÎïҽѧÑо¿ËùÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2018.5.17, 2017.3.30¼°2016.4.14; »áÒ鱨¸æ¡£
(º£±¨±¨¸æºÍÆäËû):
10. Å·ÖÞ°©Ö¢Ñо¿Ð»áµÚ25½ìË«Äê»á£¨eacr25£©£¬ºÉÀ¼°¢Ä·Ë¹Ìص¤£¬2018Äê6ÔÂ30ÈÕÖÁ7ÔÂ3ÈÕ; º£±¨Õ¹Ê¾¡£
11. µÚ¶þ½ì±±Å·²©Ê¿·å»á¡°think open¡±£¬·ÒÀ¼ºÕ¶ûÐÁ»ù´óѧ£¬2018Äê8ÔÂ23ÈÕÖÁ24ÈÕ; º£±¨Õ¹Ê¾¡£
12. ÉúÎïĤ¹ú¼ÊÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2018Äê8ÔÂ19ÈÕÖÁ22ÈÕ; º£±¨Õ¹Ê¾¡£
13. ºÕ¶ûÐÁ»ù´óѧÄê¶Èresearch program unit¿ÆѧÈÕ£¬·ÒÀ¼hanasaari£¬2018Äê6ÔÂ15ÈÕ; º£±¨Õ¹Ê¾, ¡°×î¼Ñº£±¨½±¡±¡£
14. Å·ÖÞÉú»¯Ñ§»á£¨febs£©¸ß¼¶¿Î³Ìôß2017Äê¶ÈÅ·ÖÞϸ°û¹Ç¼ÜÂÛ̳¡°Ï¸°û¹Ç¼Ü£º´ÓÖÊĤµ½Ï¸°ûºËµÄ»úеñîºÏ£¬·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2017Äê6ÔÂ4ÈÕÖÁ8ÈÕ; º£±¨Õ¹Ê¾¡£
15. wihuriÑо¿ËùÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2016Äê8ÔÂ22ÈÕÖÁ23ÈÕ; º£±¨Õ¹Ê¾¡£
16. ºÕ¶ûÐÁ»ù°©Ö¢ÉúÎïѧÊîÆÚѧУÑÐÌֻᣬ·ÒÀ¼ºÕ¶ûÐÁ»ù£¬2016Äê5ÔÂ25ÈÕ; »áÒ鱨¸æºÍº£±¨Õ¹Ê¾¡£
17. ¹ú¼Òϸ°ûÉúÎïѧ»áÒ飬ÖйúÎ人£¬2013Äê4ÔÂ19ÈÕÖÁ21ÈÕ; º£±¨Õ¹Ê¾, ¡°×î¼Ñº£±¨½±¡±¡£
18. ¡°Ñ×Ö¢ºÍÃâÒß¡± ÏîÄ¿£¬Î¬Ò²ÄÉÒ½¿Æ´óѧ£¬°ÂµØÀûάҲÄÉ£¬2014Äê6ÔÂ30ÈÕÖÁ7ÔÂ3ÈÕ; ѧÊõ·ÃÎÊ¡£ |
|